

9/10/21
B12

1. (Once Amended) A method of lowering plasma glucagon in a subject, comprising administering to said subject a therapeutically effective glucagon lowering amount of a compound selected from an exendin, an exendin agonist, a modified exendin and a modified exendin agonist.

Please add the following new claims:

9/10/21
B13

9. (New) A method of lowering plasma glucagon in a subject, comprising administering to said subject a glucagon lowering amount of at least one compound selected from a modified exendin and a modified exendin agonist.

10. (New) A method of lowering plasma glucagon in a subject, comprising administering to said subject a glucagon lowering amount of a composition consisting essentially of at least one of an exendin, an exendin agonist, a modified exendin and a modified exendin agonist.

11. (New) The method of claim 1, wherein the compound is provided in dosage unit form without another anti-glucagon agent.

12. (New) The method of claim 1, wherein the subject has a diabetes-related disorder.

13. (New) The method of claim 12, wherein the subject has type 2 diabetes.